The Brook Army Medical Center Membership includes the Brooke Army Medical Center and Wilford Hall Medical Center, Army and Air Force tertiary referral medical centers in San Antonio, Texas, respectively. In addition, it serves as the headquarters for five affiliated CGOP affiliates including Eisenhower Army Medical Center, South Georgia Medical Center, Lee Memorial Hospital, Cape Coral Hospital, and Southwest Florida Regional Medical Center. BAMC and WHMC tumor registries include a combined 1500 new cases per year. They have an integrated fellowship training program as well as combined educational activities with the University of Texas Health Science Center in San Antonio. The patients seen at the primary centers are active and retired military personnel. In the past two years, 19 percent of patients enrolled to SWOG protocols have been non-Caucasian and 44 percent have been female. The membership is led by Dr. Ian Thompson, a urologist, with support of all relevant multidisciplinary specialists. Dr. Thompson is also Chair of the BMAC/WHMC UCOP. Dr. Thompson is an acknowledged expert in genitourinary malignancies. He leads the prostate cancer prevention trial, a major effort of the SWOG program. From 1992 until the present, this membership has furnished principal investigators for four phase II trials and one cancer control trial. They have been co-coordinators for four phase II, one phase III, and one cancer control trial in the past but have protocol coordinators now. Members have been first author on six manuscripts and co-authors on nine published manuscripts. They have provided first authors for two and co-authors for three abstracts. As a member institution, they have had three individuals serve on the Board of Governors. Dr. Thompson has served as the Chair of the Localized Prostate Subcommittee.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
U.S. Brooke Army Medical Center(Ft Sam Houston)
San Antonio
United States
Zip Code
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Allen, Jeffrey W; Moon, James; Redman, Mary et al. (2014) Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol 32:2463-70
Dhodapkar, Madhav V; Sexton, Rachael; Waheed, Sarah et al. (2014) Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 123:78-85
Philip, Philip A; Goldman, Bryan; Ramanathan, Ramesh K et al. (2014) Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWO Cancer 120:2980-5

Showing the most recent 10 out of 131 publications